You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)

Article metrics

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trials in Progress
955 CORE1: phase 2, single arm study of CG0070 combined with pembrolizumab in patients with non muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG)
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

AbstractFullPdf
Nov 2021563026
Dec 2021180014
Jan 2022118015
Feb 2022138027
Mar 2022480012
Apr 2022184034
May 2022136019
Jun 2022144010
Jul 20226006
Aug 2022144014
Sep 202268012
Oct 20226604
Nov 2022228028
Dec 20227404
Jan 20236207
Feb 20239206
Mar 20234603
Apr 20235209
May 202396014
Jun 20234204
Jul 202336011
Aug 20235607
Sep 20233603
Oct 20236406
Nov 20236207
Dec 20237606
Jan 20242803
Feb 20242804
Mar 2024104034
Apr 20246606
May 20247008
Jun 202440012
Jul 202444012
Aug 20241406
Total36970393